Skip to main content
. 2022 Dec 12;26(1):105799. doi: 10.1016/j.isci.2022.105799

Figure 7.

Figure 7

Multigene biomarkers are predictive of qualitative response in other PDX datasets and in a clinical human dataset with response to cisplatin

(A) ROC of response predictions in the RMGCRC PDX cohort for complete and partial response (CR/PR) versus all else. The ROC for predictions for cisplatin is in blue, and the ROC for predictions to paclitaxel is red.

(B) ROC of response predictions in the RMGCRC PDX cohort for complete response (CR) versus all else. The ROC for predictions for cisplatin is in blue, and the ROC for predictions to paclitaxel is red.

(C) ROC of response prediction for cisplatin response in the Curie cohort.

(D) ROC of response prediction for cisplatin response in a human clinical cohort (DFCI).

(E) ROC of response prediction for paclitaxel prediction in the BrighTNess cohort. Note that the response was measured after treatment with AC as well.